(Q36395107)

13 August 2017

1 reference

title

Drug insight: Use of docetaxel in prostate and urothelial cancers (English)

1 reference

13 August 2017

1 reference

2

Kenneth J Pienta

1 reference

13 August 2017

1

Niklas J Mackler

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

13 August 2017

published in

Nature Reviews Urology

1 reference

13 August 2017

volume

2

1 reference

13 August 2017

issue

2

1 reference

13 August 2017

page(s)

92-100; quiz 1 p following 112

1 reference

https://scigraph.springernature.com/pub.10.1038/ncpuro0099

13 August 2017

exact match

0 references

cites work

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0099

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0099

Microtubules, microtubule-interfering agents and apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0099

Microtubule-interacting drugs for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0099

Dynamic instability of microtubule growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0099

Microtubules as a target for anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0099

Opposite end assembly and disassembly of microtubules at steady state in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0099

Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0099

bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0099

Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0099

Weekly administration of docetaxel for symptomatic metastatic hormone‐refractory prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0099

Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0099

Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0099

Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0099

Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0099

A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0099

Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0099

Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0099

Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0099

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0099

7 January 2021

Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0099

7 January 2021

Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0099

7 January 2021

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0099

7 January 2021

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0099

7 January 2021

Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0099

7 January 2021

Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0099

7 January 2021

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0099

7 January 2021

Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0099

7 January 2021

Identifiers

DOI

10.1038/NCPURO0099

1 reference

release_jewoi4ftwfadjkemakme33ho2a

13 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jewoi4ftwfadjkemakme33ho2a

24 November 2022

mapped directly with Wikidata item

1 reference